INNO-206 in Patients With Small Cell Lung Cancer (SCLC)

A Phase II, Open-label Study of INNO-206 in Patients With Recurrent Extensive Small Cell Lung Cancer After First-line Platinum-based Therapy

The purpose of this study is to determine whether INNO-206 is effective in the treatment of small cell lung cancer.

Study Overview

• Status: Withdrawn
• Conditions: Small Cell Lung Cancer
• Intervention / Treatment: Drug: INNO-206

Detailed Description

This is a phase II, open-label, prospective, multicenter, single-arm study of INNO 206 in adult patients with recurrent extensive small cell lung cancer sensitive to first-line platinum-based therapy. The primary objective of the study is to determine the objective overall response rate. Secondary objectives include evaluating the treatment-related toxicities in this patient population and determining the pharmacokinetic (PK) profile of INNO-206 in a minimum of 12 patients.

• Study Type: Interventional
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Illinois
    • Chicago, Illinois, United States, 60637
      • University of Chicago
  • Montana
    • Billings, Montana, United States, 59107
      • Billings Clinic
  • New York
    • Albany, New York, United States, 12206
      • New York Oncology Hematology, P.C.
  • Ohio
    • Kettering, Ohio, United States, 45409
      • Dayton Oncology And Hematology
    • Middletown, Ohio, United States, 45042
      • Signal Point Hematology/Oncology, Inc.
  • South Carolina
    • Greenville, South Carolina, United States, 29605
      • Cancer Centers of the Carolinas
  • Texas
    • Dallas, Texas, United States, 75246
      • Mary Crowley Medical Research Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Be ≥18 years old.
• Have a histologically or cytologically confirmed diagnosis of recurrent extensive small cell lung cancer (SCLC) at the time of enrollment into the study.
• Have responded to first-line platinum-based chemotherapy, but progressed or relapsed ≥60 days after completion of first-line therapy.
• Have measurable disease defined by RECIST.
• Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤2.
• Have an estimated life expectancy of ≥4 weeks.
• Be male or non-pregnant, non-lactating female patients. Patients who are fertile must agree to use an effective barrier method of birth control to avoid pregnancy while on therapy and for 90 days following the discontinuation of the study medication.
• Have a negative serum or urine pregnancy test within 7 days prior to the first dose of study medication (if patient is a female of childbearing potential).
• Have adequate organ function.

Exclusion Criteria:

• Are pregnant or lactating.
• Have received prior anthracycline therapy.
• Have participated in any investigational drug study within 30 days prior to study entry.
• Have received radiotherapy within 2 weeks of treatment in this study.
• Have not recovered from acute toxicity of all previous therapy prior to enrollment.
• Have a history of a malignancy other than SCLC. Exceptions to this include: curatively treated nonmelanomatous carcinoma of the skin or in situ carcinoma of the cervix, or prior low-grade, localized prostate cancer (Gleason score ≤6); or a history of another malignancy that was curatively treated and no evidence of recurrence for a minimum of 5 years.
• Have symptomatic central nervous system (CNS) metastases.
• Have any concurrent severe or uncontrolled medical disease (such as active systemic infection, hypertension, congestive heart failure ≥NYHA Grade II, myocardial infarction within 6 months before study start, severe rhythm disturbances, etc.) that, in the opinion of the Investigator, would compromise the safety of the patient or compromise the ability of the patient to complete the study.
• Have a psychiatric disorder(s) that would interfere with consent, study participation, or follow-up.
• Have received radiotherapy with >25% involvement of the bone marrow within 6 weeks prior to study start.
• Have a known hypersensitivity to doxorubicin, 5% D-(+)-sucrose, 10 mM sodium phosphate, and/or 0.3% N-acetyltryptophane.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
To determine the objective overall response rate (OR; complete [CR] and partial [PR] responses).

Secondary Outcome Measures

Outcome Measure
To determine the rates of stable disease and progressive disease.
To determine time to progression.
To determine progression-free survival.
To determine overall survival.
To evaluate the treatment-related toxicities in this patient population.
To determine the pharmacokinetic profile of INNO-206 in a minimum of 12 patients.

Collaborators and Investigators

• Sponsor: CytRx
• Investigators: Principal Investigator: Michael Maitland, MD, University of Chicago

Study record dates

Study Major Dates

• Study Start: May 1, 2008
• Primary Completion: December 7, 2022
• Study Completion (Actual): November 1, 2008

Study Registration Dates

• First Submitted: May 11, 2007
• First Submitted That Met QC Criteria: May 11, 2007
• First Posted (Estimate): May 14, 2007

Study Record Updates

• Last Update Posted (Estimate): February 9, 2012
• Last Update Submitted That Met QC Criteria: February 8, 2012
• Last Verified: February 1, 2012

More Information

Terms related to this study

• Keywords: Recurrent extensive small cell lung cancer
• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Neoplasms; Lung Diseases; Neoplasms by Site; Respiratory Tract Neoplasms; Thoracic Neoplasms; Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Small Cell Lung Carcinoma
• Other Study ID Numbers: INNO-206-P2

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No